Genotypes and Phenotypes and Predicting Disease Severity in Patients with CF

In this module of the Eight-Part Cystic Fibrosis Series, Dr. Jennifer Taylor-Cousar and Dr. John P. Clancy will enlarge on genotyping and phenotyping in cystic fibrosis (CF), particularly its effect on predicting disease severity in patients. Dr. Taylor-Cousar will briefly review the anatomy of a CFTR gene, followed by a comprehensive explanation of existing mutations in CF and their prevalence. Methods of classifying CFTR mutations, in order to provide optimal patient care, will be relayed to learners. The faculty will also highlight the discrepancies between a classic CF diagnosis in childhood and a non-classic CF diagnosis in adulthood. As CF treatment and management is becoming more complex, understanding genotyping and phenotyping will be key in improving patient outcomes.

TARGET AUDIENCE

These activities are designed for physicians, nurses, and other healthcare professionals involved in the management of patients with cystic fibrosis.

LEARNING OUTCOME STATEMENTS

At the conclusion of this activity:

KNOWLEDGE: Participants will self-report know knowledge gained based on genotyping and phenotyping in cystic fibrosis (CF).

COMPETENCE/SKILL: Participants will self-report intent to change practice by utilizing genotyping and phenotyping as it relates to predicting disease severity in CF patients.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Understand genotyping and phenotyping as it relates to predicting disease severity in CF patients

FACULTY

John P. Clancy, MD (Chair)
Professor of Pediatrics
Director, Pulmonary Medicine Research
Co- Director, CF Research Development Program
Medical Director, Office of Clinical and Translational Research
Gunnar Esiason/Cincinnati Bell Chair in Life Sciences Research
Division of Pulmonary Medicine
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Jennifer L. Taylor-Cousar, MD, MSCS
Associate Professor of Medicine and Pediatrics,
Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine
Co-Director and CF TDN Director, Adult CF Program
National Jewish Health
Denver, Colorado

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education and Elsevier ANCC accredited provider unit that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.  

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
John P. Clancy, MD

Consultant/Advisor: Gilead

Grant/Research Support: Bayer AG, Concert Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, ProQR Therapeutics

Speaker's Bureau: Genentech, Inc.

Jennifer L. Taylor-Cousar, MD, MSCS

Consultant/Advisor: Gilead; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Proteostasis Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated

Grant/Research Support: Gilead; Vertex Pharmaceuticals Incorporated

Speaker's Bureau: Vertex Pharmaceuticals Incorporated

Non-faculty: Sandy Breslow; Alison Kemp; Marilu Kelly, MSN, RN, CNE; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Chelsey Benedek hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

PROVIDER INFORMATION

Provided in collaboration with the Elsevier Office of Continuing Medical Education, Elsevier and AcademicCME.

CME CREDIT (PHYSICIANS)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE CREDIT (NURSES)

This continuing nursing education activity, provided by Elsevier, awards 0.43 contact hours for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and AcademicCME. EOCME is accredited by the ACCME to provide continuing medical education for physicians.

CME/CNE INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

For all CNE inquiries or special needs, please contact p.harvey@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, AcademicCME and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.43 Nursing Contact Hours
  • 0.50 Non-physician
Course opens: 
09/15/2017
Course expires: 
09/14/2018
Rating: 
0

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.43 Nursing Contact Hours
  • 0.50 Non-physician

Accreditation Period

Course opens: 
09/15/2017
Course expires: 
09/14/2018
Please login or register to take this course.